Bokarewa Maria, Dahlberg Leif, Tarkowski Andrej
Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, Göteborg, Sweden.
Arthritis Res Ther. 2005;7(5):R1014-22. doi: 10.1186/ar1771. Epub 2005 Jun 22.
Tissue inhibitors of matrix metalloproteinases (TIMPs) regulate the breakdown of extracellular matrix components and play an important role in tissue remodelling and growth, in both physiological and pathological conditions. We studied the autoimmune response to TIMPs in patients with rheumatoid arthritis (RA). Eighty-nine paired blood and synovial fluid samples from patients with RA were assessed for their reactivity with recombinant tissue inhibitors of metalloproteinases (TIMPs) 1 to 4 by an ELISA and were compared with blood from 62 healthy controls and 21 synovial fluid samples from patients with degenerative joint diseases. Presence of antibodies was established as the absorbance of the sample more than 2 standard deviations above the mean of the controls. In addition, immunoglobulin G (IgG) from blood samples of RA patients possessing TIMP antibodies was isolated on protein A-sepharose and tested for the in vitro ability to neutralize TIMP-2-dependent effects on metalloproteinase 9 (MMP9). Anti-TIMP antibodies were found in 56% of RA samples but in only 5% of the controls (P < 0.005). RA patients had high frequencies of antibodies against all TIMPs except TIMP-3. TIMP-2 antibodies were most frequently found (33%), being significantly more prevalent (P = 0.024) in patients with nonerosive than erosive RA. TIMP-1 antibodies were significantly more often found in synovial fluid samples than in the matched blood samples (P < 0.025). Importantly, the IgG fraction containing TIMP antibodies down-regulated the TIMP-2 inhibitory effect, thereby supporting MMP9 activity in vitro. In the present study, we show that RA patients frequently develop autoimmune response to TIMPs that may act as a functionally significant regulator of MMP activity and thereby of joint destruction.
基质金属蛋白酶组织抑制剂(TIMPs)可调节细胞外基质成分的降解,在生理和病理条件下的组织重塑与生长过程中发挥重要作用。我们研究了类风湿关节炎(RA)患者对TIMPs的自身免疫反应。采用酶联免疫吸附测定法(ELISA),对89例RA患者的配对血液和滑液样本与重组基质金属蛋白酶组织抑制剂(TIMPs)1至4的反应性进行了评估,并与62例健康对照者的血液以及21例退行性关节疾病患者的滑液样本进行了比较。当样本吸光度高于对照均值2个标准差以上时,判定存在抗体。此外,利用蛋白A-琼脂糖从具有TIMP抗体的RA患者血液样本中分离出免疫球蛋白G(IgG),并检测其在体外中和TIMP-2对金属蛋白酶9(MMP9)依赖性作用的能力。在56%的RA样本中发现了抗TIMP抗体,而在对照样本中仅为5%(P<0.005)。RA患者中除TIMP-3外,针对所有TIMPs的抗体频率均较高。TIMP-2抗体最为常见(33%),在非侵蚀性RA患者中的发生率显著高于侵蚀性RA患者(P = 0.024)。TIMP-1抗体在滑液样本中的发现频率显著高于配对的血液样本(P<0.025)。重要的是,含有TIMP抗体的IgG组分下调了TIMP-2的抑制作用,从而在体外支持了MMP9的活性。在本研究中,我们表明RA患者经常对TIMPs产生自身免疫反应,这可能作为MMP活性的功能重要调节因子,进而成为关节破坏的调节因子。